Treatment of Primary or Metastatic Pleural Effusion with Intracavitary Cytosine Arabinoside and Cisplatin: A phase II study
Thirty-three patients with microscopically verified primary or metastatic malignant pleural effusion were studied: 7 had malignant mesothelioma and 26 metastatic pleural disease. The treatment was based on biochemical and clinical studies which show a synergy between cytosine-arabinoside (Ara-C) and...
Gespeichert in:
| Veröffentlicht in: | Acta oncologica 1994, Vol.33 (2), p.191-194 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 194 |
|---|---|
| container_issue | 2 |
| container_start_page | 191 |
| container_title | Acta oncologica |
| container_volume | 33 |
| creator | Aitini, Enrico Cavazzini, Giovanna Pasquini, Enzo Rabbi, Carla Colombo, Fausto Cantore, Maurizio Fattori, Pier Paolo Pari, Franca Bertuzzi, Alberto Smerieri, Franco |
| description | Thirty-three patients with microscopically verified primary or metastatic malignant pleural effusion were studied: 7 had malignant mesothelioma and 26 metastatic pleural disease. The treatment was based on biochemical and clinical studies which show a synergy between cytosine-arabinoside (Ara-C) and cisplatin. These drugs were instilled in the pleural cavity at the dose of 100 mg for Ara-C and 100 mg/m2 for cisplatin. The cavity was drained after 4 h. If it was possible, the treatment was repeated weekly for 3 times and, after a 6-week rest, it could be started again with the same schedule. The overall response rate (complete plus partial remissions) was 74%. Toxicity was mild or moderate. We conclude that the combination of Ara-C and cisplatin is well tolerated and produces a high response rate in the treatment of malignant pleural effusions. |
| doi_str_mv | 10.3109/02841869409098404 |
| format | Article |
| fullrecord | <record><control><sourceid>informahealthcare_cross</sourceid><recordid>TN_cdi_crossref_primary_10_3109_02841869409098404</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_3109_02841869409098404</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-87cb27654b9a2382f488068a41f6d74bfa5fbadcf052b6728b09ddb19aa9a48c3</originalsourceid><addsrcrecordid>eNp9kEFLAzEQhYMotVZ_gAchB6-rSZrdzeqplKqFij1U6G2ZZBOass2WJKsU_7xbWnoRPM3A-94w7yF0S8nDkJLikTDBqcgKTgpSCE74GerTLKUJY9nyHPX3etIBy0t0FcKaEMKGedpDPcEIZ3naRz8LryFutIu4MXju7Qb8Djcev-sIIUK0Cs9r3Xqo8cSYNtjG4W8bV3jqogcFXzbuHeNdbIJ1Go88SOu6vdIYXIXHNmzr7ox7wiO8XUHQeDrFIbbV7hpdGKiDvjnOAfp8mSzGb8ns43U6Hs0SxRmJiciVZHmWclkAGwpmuBAkE8CpyaqcSwOpkVApQ1Ims5wJSYqqkrQAKIALNRwgerirfBOC16bcHnKWlJT7Hss_PXaeu4Nn28qNrk6OY3Gdfn_UISiojQenbDhhnHKRMdJhzwfMOtP4Daw01HGlwOty3bTedbH_eeIXsuSOrA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Treatment of Primary or Metastatic Pleural Effusion with Intracavitary Cytosine Arabinoside and Cisplatin: A phase II study</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via Taylor & Francis</source><creator>Aitini, Enrico ; Cavazzini, Giovanna ; Pasquini, Enzo ; Rabbi, Carla ; Colombo, Fausto ; Cantore, Maurizio ; Fattori, Pier Paolo ; Pari, Franca ; Bertuzzi, Alberto ; Smerieri, Franco</creator><creatorcontrib>Aitini, Enrico ; Cavazzini, Giovanna ; Pasquini, Enzo ; Rabbi, Carla ; Colombo, Fausto ; Cantore, Maurizio ; Fattori, Pier Paolo ; Pari, Franca ; Bertuzzi, Alberto ; Smerieri, Franco</creatorcontrib><description>Thirty-three patients with microscopically verified primary or metastatic malignant pleural effusion were studied: 7 had malignant mesothelioma and 26 metastatic pleural disease. The treatment was based on biochemical and clinical studies which show a synergy between cytosine-arabinoside (Ara-C) and cisplatin. These drugs were instilled in the pleural cavity at the dose of 100 mg for Ara-C and 100 mg/m2 for cisplatin. The cavity was drained after 4 h. If it was possible, the treatment was repeated weekly for 3 times and, after a 6-week rest, it could be started again with the same schedule. The overall response rate (complete plus partial remissions) was 74%. Toxicity was mild or moderate. We conclude that the combination of Ara-C and cisplatin is well tolerated and produces a high response rate in the treatment of malignant pleural effusions.</description><identifier>ISSN: 0284-186X</identifier><identifier>EISSN: 1651-226X</identifier><identifier>DOI: 10.3109/02841869409098404</identifier><identifier>PMID: 8204275</identifier><identifier>CODEN: ACTOEL</identifier><language>eng</language><publisher>Basingstoke: Informa UK Ltd</publisher><subject>Adult ; Aged ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Chemotherapy ; Cisplatin - administration & dosage ; Cytarabine - administration & dosage ; Female ; Humans ; Instillation, Drug ; Male ; Medical sciences ; Mesothelioma - drug therapy ; Mesothelioma - secondary ; Middle Aged ; Pharmacology. Drug treatments ; Pleural Effusion, Malignant - drug therapy ; Remission Induction ; Treatment Outcome</subject><ispartof>Acta oncologica, 1994, Vol.33 (2), p.191-194</ispartof><rights>1994 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1994</rights><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-87cb27654b9a2382f488068a41f6d74bfa5fbadcf052b6728b09ddb19aa9a48c3</citedby><cites>FETCH-LOGICAL-c420t-87cb27654b9a2382f488068a41f6d74bfa5fbadcf052b6728b09ddb19aa9a48c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.3109/02841869409098404$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.3109/02841869409098404$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>315,782,786,4026,27930,27931,27932,61228,61409</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4148620$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8204275$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aitini, Enrico</creatorcontrib><creatorcontrib>Cavazzini, Giovanna</creatorcontrib><creatorcontrib>Pasquini, Enzo</creatorcontrib><creatorcontrib>Rabbi, Carla</creatorcontrib><creatorcontrib>Colombo, Fausto</creatorcontrib><creatorcontrib>Cantore, Maurizio</creatorcontrib><creatorcontrib>Fattori, Pier Paolo</creatorcontrib><creatorcontrib>Pari, Franca</creatorcontrib><creatorcontrib>Bertuzzi, Alberto</creatorcontrib><creatorcontrib>Smerieri, Franco</creatorcontrib><title>Treatment of Primary or Metastatic Pleural Effusion with Intracavitary Cytosine Arabinoside and Cisplatin: A phase II study</title><title>Acta oncologica</title><addtitle>Acta Oncol</addtitle><description>Thirty-three patients with microscopically verified primary or metastatic malignant pleural effusion were studied: 7 had malignant mesothelioma and 26 metastatic pleural disease. The treatment was based on biochemical and clinical studies which show a synergy between cytosine-arabinoside (Ara-C) and cisplatin. These drugs were instilled in the pleural cavity at the dose of 100 mg for Ara-C and 100 mg/m2 for cisplatin. The cavity was drained after 4 h. If it was possible, the treatment was repeated weekly for 3 times and, after a 6-week rest, it could be started again with the same schedule. The overall response rate (complete plus partial remissions) was 74%. Toxicity was mild or moderate. We conclude that the combination of Ara-C and cisplatin is well tolerated and produces a high response rate in the treatment of malignant pleural effusions.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Cytarabine - administration & dosage</subject><subject>Female</subject><subject>Humans</subject><subject>Instillation, Drug</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mesothelioma - drug therapy</subject><subject>Mesothelioma - secondary</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Pleural Effusion, Malignant - drug therapy</subject><subject>Remission Induction</subject><subject>Treatment Outcome</subject><issn>0284-186X</issn><issn>1651-226X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEFLAzEQhYMotVZ_gAchB6-rSZrdzeqplKqFij1U6G2ZZBOass2WJKsU_7xbWnoRPM3A-94w7yF0S8nDkJLikTDBqcgKTgpSCE74GerTLKUJY9nyHPX3etIBy0t0FcKaEMKGedpDPcEIZ3naRz8LryFutIu4MXju7Qb8Djcev-sIIUK0Cs9r3Xqo8cSYNtjG4W8bV3jqogcFXzbuHeNdbIJ1Go88SOu6vdIYXIXHNmzr7ox7wiO8XUHQeDrFIbbV7hpdGKiDvjnOAfp8mSzGb8ns43U6Hs0SxRmJiciVZHmWclkAGwpmuBAkE8CpyaqcSwOpkVApQ1Ims5wJSYqqkrQAKIALNRwgerirfBOC16bcHnKWlJT7Hss_PXaeu4Nn28qNrk6OY3Gdfn_UISiojQenbDhhnHKRMdJhzwfMOtP4Daw01HGlwOty3bTedbH_eeIXsuSOrA</recordid><startdate>1994</startdate><enddate>1994</enddate><creator>Aitini, Enrico</creator><creator>Cavazzini, Giovanna</creator><creator>Pasquini, Enzo</creator><creator>Rabbi, Carla</creator><creator>Colombo, Fausto</creator><creator>Cantore, Maurizio</creator><creator>Fattori, Pier Paolo</creator><creator>Pari, Franca</creator><creator>Bertuzzi, Alberto</creator><creator>Smerieri, Franco</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>1994</creationdate><title>Treatment of Primary or Metastatic Pleural Effusion with Intracavitary Cytosine Arabinoside and Cisplatin: A phase II study</title><author>Aitini, Enrico ; Cavazzini, Giovanna ; Pasquini, Enzo ; Rabbi, Carla ; Colombo, Fausto ; Cantore, Maurizio ; Fattori, Pier Paolo ; Pari, Franca ; Bertuzzi, Alberto ; Smerieri, Franco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-87cb27654b9a2382f488068a41f6d74bfa5fbadcf052b6728b09ddb19aa9a48c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Cytarabine - administration & dosage</topic><topic>Female</topic><topic>Humans</topic><topic>Instillation, Drug</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mesothelioma - drug therapy</topic><topic>Mesothelioma - secondary</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Pleural Effusion, Malignant - drug therapy</topic><topic>Remission Induction</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aitini, Enrico</creatorcontrib><creatorcontrib>Cavazzini, Giovanna</creatorcontrib><creatorcontrib>Pasquini, Enzo</creatorcontrib><creatorcontrib>Rabbi, Carla</creatorcontrib><creatorcontrib>Colombo, Fausto</creatorcontrib><creatorcontrib>Cantore, Maurizio</creatorcontrib><creatorcontrib>Fattori, Pier Paolo</creatorcontrib><creatorcontrib>Pari, Franca</creatorcontrib><creatorcontrib>Bertuzzi, Alberto</creatorcontrib><creatorcontrib>Smerieri, Franco</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Acta oncologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aitini, Enrico</au><au>Cavazzini, Giovanna</au><au>Pasquini, Enzo</au><au>Rabbi, Carla</au><au>Colombo, Fausto</au><au>Cantore, Maurizio</au><au>Fattori, Pier Paolo</au><au>Pari, Franca</au><au>Bertuzzi, Alberto</au><au>Smerieri, Franco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of Primary or Metastatic Pleural Effusion with Intracavitary Cytosine Arabinoside and Cisplatin: A phase II study</atitle><jtitle>Acta oncologica</jtitle><addtitle>Acta Oncol</addtitle><date>1994</date><risdate>1994</risdate><volume>33</volume><issue>2</issue><spage>191</spage><epage>194</epage><pages>191-194</pages><issn>0284-186X</issn><eissn>1651-226X</eissn><coden>ACTOEL</coden><abstract>Thirty-three patients with microscopically verified primary or metastatic malignant pleural effusion were studied: 7 had malignant mesothelioma and 26 metastatic pleural disease. The treatment was based on biochemical and clinical studies which show a synergy between cytosine-arabinoside (Ara-C) and cisplatin. These drugs were instilled in the pleural cavity at the dose of 100 mg for Ara-C and 100 mg/m2 for cisplatin. The cavity was drained after 4 h. If it was possible, the treatment was repeated weekly for 3 times and, after a 6-week rest, it could be started again with the same schedule. The overall response rate (complete plus partial remissions) was 74%. Toxicity was mild or moderate. We conclude that the combination of Ara-C and cisplatin is well tolerated and produces a high response rate in the treatment of malignant pleural effusions.</abstract><cop>Basingstoke</cop><pub>Informa UK Ltd</pub><pmid>8204275</pmid><doi>10.3109/02841869409098404</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0284-186X |
| ispartof | Acta oncologica, 1994, Vol.33 (2), p.191-194 |
| issn | 0284-186X 1651-226X |
| language | eng |
| recordid | cdi_crossref_primary_10_3109_02841869409098404 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via Taylor & Francis |
| subjects | Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Chemotherapy Cisplatin - administration & dosage Cytarabine - administration & dosage Female Humans Instillation, Drug Male Medical sciences Mesothelioma - drug therapy Mesothelioma - secondary Middle Aged Pharmacology. Drug treatments Pleural Effusion, Malignant - drug therapy Remission Induction Treatment Outcome |
| title | Treatment of Primary or Metastatic Pleural Effusion with Intracavitary Cytosine Arabinoside and Cisplatin: A phase II study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T16%3A41%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-informahealthcare_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20Primary%20or%20Metastatic%20Pleural%20Effusion%20with%20Intracavitary%20Cytosine%20Arabinoside%20and%20Cisplatin:%20A%20phase%20II%20study&rft.jtitle=Acta%20oncologica&rft.au=Aitini,%20Enrico&rft.date=1994&rft.volume=33&rft.issue=2&rft.spage=191&rft.epage=194&rft.pages=191-194&rft.issn=0284-186X&rft.eissn=1651-226X&rft.coden=ACTOEL&rft_id=info:doi/10.3109/02841869409098404&rft_dat=%3Cinformahealthcare_cross%3E10_3109_02841869409098404%3C/informahealthcare_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/8204275&rfr_iscdi=true |